2. >>Leadership

A Day Job And A Gay Job: How OUTbio Is Connecting LGBTQ Biotech Executives

Networking Organization Now Has Branches Across The US, UK And Ireland

 
• By Chloe Kent

LGBTQ networking group OUTbio has gone from strength to strength since it was founded in 2015, from a small event attended by a handful of executives in Boston to a registered non-profit with affiliated groups across the US alongside international branches.

Pride flag billowing in the air
• Source: Shutterstock

“I always start by saying I have a day job and a gay job,” opened OUTbio founder Ramsey Johnson. By day, Johnson works as vice president of clinical operations of Aditum Bio. In his spare time, he runs the non-profit OUTbio, a growing LGBTQ professionals group for the biotech industry.

Since it was set up eight years ago, OUTbio has gone from being an informal organization to a fully-fledged non-profit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By Jo Shorthouse

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.